Steglujan Film-coated tablet Arab Saudi - Inggeris - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

steglujan film-coated tablet

merck sharp & dohme b.v, netherlands - sitagliptin phosphate,ertugliflozin - film-coated tablet - 100,15 mg,

SITAGLIPTIN SUN sitagliptin 100 mg (as fumarate) tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sitagliptin sun sitagliptin 100 mg (as fumarate) tablet blister pack

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 128.497 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

SITAGLIPTIN SUN sitagliptin 25 mg (as fumarate) tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sitagliptin sun sitagliptin 25 mg (as fumarate) tablet blister pack

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 32.124 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

SITAGLIPTIN SUN sitagliptin 50 mg (as fumarate) tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sitagliptin sun sitagliptin 50 mg (as fumarate) tablet blister pack

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 64.249 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

XELEVIA sitagliptin (as phosphate monohydrate) 25 mg film-coated tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

xelevia sitagliptin (as phosphate monohydrate) 25 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 32.13 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

XELEVIA sitagliptin (as phosphate monohydrate) 50 mg film-coated tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

xelevia sitagliptin (as phosphate monohydrate) 50 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.